The anatomic pathology market size is projected to reach US$ 53.27 billion by 2031 from US$ 30.22 billion in 2023. The market is expected to register a CAGR of 7.3% during 2023–2031. The integration of artificial intelligence and machine learning is likely to act as a future trend in the market.
Innovations in diagnostic techniques—including digital pathology, molecular diagnostics, and imaging technologies—enhance the accuracy and efficiency of pathology services, propelling the anatomic pathology market growth. An aging population is more susceptible to various diseases, leading to increased demand for pathology services for accurate diagnosis and treatment planning. In addition, increased awareness about health issues, robust screening programs contributing to early diagnosis, supportive regulatory frameworks, and favorable reimbursement policies are fueling the growth of the anatomic pathology market.
India is expected to register the highest CAGR in the overall market. The National Cancer Registry Programme Report 2020 projected cancer cases in India to reach 14.61 million in 2022. The report also stated that the incidence of cancer is estimated to increase by 12.8% by 2025 compared to 2020. With the surging prevalence of cancer and advancements in healthcare infrastructure, government authorities in India are focusing on providing people with extended access to healthcare solutions. As per data by the Department for Promotion of Industry and Internal Trade (DPIIT), the inflow of foreign direct investments (FDIs) into the drugs and pharmaceuticals industry totaled US$ 17.74 billion from April 2000 to December 2020. Moreover, companies, organizations, governments, etc., make significant investments in diagnostic services and modern diagnostic facilities. Thus, such investments in the healthcare sector bolster the anatomic pathology market growth in India.
Anatomic pathology is useful in identifying abnormalities that can help diagnose diseases, such as autoimmune diseases, kidney and liver diseases, and cancer. Histopathology, which involves studying tissue changes caused by diseases, is a vital part of anatomic pathology. Cancer has a major impact on society across the world. The burden of cancer on healthcare systems is significantly increasing worldwide as it is among the leading causes of death. The World Health Organization (WHO) ranks cancer as the second-leading cause of mortality worldwide. According to data published by the World Cancer Research Fund International, ~20 million new cases of cancer were registered in 2022 globally. Moreover, as per the data published by the World Health Organization (WHO), nearly 10 million deaths worldwide were caused by cancer in 2020. The National Center for Health Statistics data estimates that the diagnosis of new cancer cases in the US is likely to reach 2 million in 2024. In addition, ~0.61 million people are likely to die in 2024 in the US due to cancer. According to data published by Macmillan Cancer Support, ~392,000 people in the UK are diagnosed with cancer every year, while ~167,000 people die due to the disease each year.
The prevalence of chronic kidney disease is growing due to the increase in the geriatric population. According to the Centers for Disease Control and Prevention, in 2023, ~35.5 million people in the US suffered from chronic kidney diseases. Biopsy, an anatomic pathology technique, is used for the detection of cancer and chronic kidney disease. Owing to the increasing prevalence of cancer and kidney disease, government agencies, healthcare providers, and institutions are being compelled to contribute toward disease diagnosis and treatment initiatives. Thus, a surge in the prevalence of cancer and other targeted diseases, such as autoimmune diseases, and kidney and liver diseases is driving the global anatomic pathology market growth.
Personalized medicines are mainly designed by considering individuals' genetic profiles to guide the decisions made with respect to the prevention, diagnosis, and treatment of a disease. They provide an opportunity for drug manufacturers to develop agents that target patient groups that do not respond to medications as intended or for them who do not respond as expected to traditional healthcare practices. There is much evidence indicating that a substantial portion of the variability in drug response depends on factors that are genetically controlled, including age, nutrition, environmental exposure, and health status. Genomics plays an important role in the emergence of personalized medicines, as having the knowledge of a patient's genetic profile would help doctors in selecting an apt medication. Personalized medicines are helpful in improving healthcare by enabling each patient to receive earlier diagnoses, risk assessments, and optimal treatments.
Pathologists play an important role in developing and implementing molecular and genomic tests in practice. Personalized medicines are used in the treatment of diseases such as breast cancer and cardiovascular diseases. Personalized anticancer medicines exhibit fewer and less severe side effects than other types of treatment as they are designed for more specific action. Further, with the ongoing progress in research and clinical studies, personalized medicines are likely to reach even greater potential to improve the quality of patient care. Thus, the growing focus on personalized medicines is expected to boost the anatomic pathology market growth.
Key segments that contributed to the derivation of the anatomic pathology market analysis are products and services, application, and end user.
The geographic scope of the anatomic pathology market report is mainly divided into five regions: North America, Asia Pacific, Europe, the South & Central America, and the Middle East & Africa. North America dominated the market in 2023. The growth of the market in this region is attributed to the growing prevalence of cancer, increasing government initiatives for screening cancer patients, rising focus on efficient disease diagnosis, and surging need for advanced healthcare systems. Moreover, increased research and development efforts undertaken by the market players, coupled with product launches, are likely to drive the growth of the anatomic pathology market in North America during the forecast period. Players operating in the US anatomic pathology market continuously focus on the development of innovative and convenient instruments and consumables for pathological procedures. In November 2023, Illumina Inc., US, a global leader in DNA sequencing and array-based technologies, introduced TruSight Oncology 500 ctDNA v2 (plate number 1 ctDNA v2), a new version of its distributed liquid biopsy assay that allows comprehensive noninvasive genomic profiling of circulating tumor DNA from blood, complementing tissue-based testing. Asia Pacific is anticipated to register the highest CAGR during the forecast period.
The regional trends and factors influencing the Anatomic Pathology Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Anatomic Pathology Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 30.22 Billion |
| Market Size by 2031 | US$ 53.27 Billion |
| Global CAGR (2023 - 2031) | 7.3% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product and Services
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Anatomic Pathology Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Anatomic Pathology Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The anatomic pathology market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the market are listed below:
The "Anatomic Pathology Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:
The List of Companies - Anatomic Pathology Market
The anatomic pathology market value is expected to reach US$ 53.27 billion by 2031.
The market is expected to register a CAGR of 7.3% during 2023–2031.
The services segment dominated the global anatomic pathology market and held the largest revenue share of 40.04% in 2021.
F. Hoffmann-La Roche Ltd, Beckman Coulter Inc, Hologic Inc, Agilent Technologies Inc, BioGenex Laboratories Inc, Diapath S.p.A., Bio SB, Merck KGaA, BD, and PHC Holdings Corporation are among the key players in the market.
The integration of artificial intelligence and machine learning is expected to be a prime trend in the market in the coming years.
North America dominated the market in 2023.
The increase in the prevalence of cancer and kidney diseases and the rise in the number of strategic initiatives are among the most significant factors fueling the market growth.